[Drug therapy of cervical cancer].
D000477:Alkylating Agents / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D010478:Chemotherapy, Cancer, Regional Perfusion; D003520:Cyclophosphamide / Q000627:therapeutic use; D004351:Drug Resistance; D004358:Drug Therapy / Q000379:methods; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008208:Lymphatic System; D008466:Mechlorethamine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D008937:Mitomycins / Q000627:therapeutic use; D011033:Podophyllin / Q000627:therapeutic use; D011300:Preoperative Care; D013852:Thiotepa / Q000627:therapeutic use; D014228:Triaziquone / Q000627:therapeutic use; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D014747:Vinblastine / Q000627:therapeutic use
D000477:Alkylating Agents; D000903:Antibiotics, Antineoplastic; D000963:Antimetabolites; D008937:Mitomycins; D008466:Mechlorethamine; D014747:Vinblastine; D003520:Cyclophosphamide; D011033:Podophyllin; D013852:Thiotepa; D014228:Triaziquone; D005472:Fluorouracil; D008727:Methotrexate
Lekarstvennaia terapiia raka sheĭki matki